LL-37

Plain-English version: LL-37 is a small piece of protein — a "peptide" — that your immune system releases to kill germs and coordinate the early immune response. It is not a foreign drug in the way most peptides are; your body makes it every single day. The research-compound version is a synthetic copy of that natural human molecule.

The name is literal. LL-37 is 37 amino acids long and begins with two leucine residues, so "LL" plus "37." It is the mature, active fragment cut from a larger precursor protein called hCAP18 (human cathelicidin antimicrobial protein, 18 kDa). Neutrophils and other cells store hCAP18, then an enzyme (proteinase 3) snips it to release LL-37 at sites of infection and injury.^[1] Importantly, LL-37 is the only member of the cathelicidin family that humans make — most animals have several, we have exactly one, which is why it does so many jobs.^[2]

You produce LL-37 wherever your body meets the outside world: the skin, the airways, the gut lining, and the urinary tract. Its production is switched on by vitamin D, which is one reason vitamin D deficiency is linked to higher infection risk — low vitamin D means less of this natural antibiotic on tap. Beyond killing microbes directly, LL-37 acts as a signaling molecule ("alarmin") that recruits immune cells, tunes inflammation, and supports wound repair.^[1]

The credibility caveat, stated up front: a molecule being natural does not make an injected copy safe or effective. The published human evidence for using LL-37 as a treatment is thin and specific — two controlled trials, both applying it topically to leg ulcers. LL-37 is not approved as a drug anywhere, and there is no approved injectable or systemic product. It is worth noting that LL-37 is not among the seven peptides on the FDA's July 2026 503A compounding advisory list; it simply sits in the unapproved research-chemical category. For the full legal picture, see Are Peptides Legal?

Takeaway first: LL-37 is a shape-shifter with two very different jobs. Job one is brute-force germ killing — it physically disrupts microbial membranes. Job two is immune signaling — it calls in immune cells and adjusts inflammation up or down depending on concentration. That second job is where both its promise and its danger live.

1. Membrane disruption — the physical kill switch

LL-37 is an amphipathic alpha-helical peptide, which is a technical way of saying it folds into a spiral with a water-loving side and a fat-loving side. That structure lets it insert into the fatty membrane of a bacterium and punch pores in it, causing the cell to leak and die.^[2] Because this is a physical attack on the membrane rather than a lock-and-key hit on one metabolic pathway, it is much harder for bacteria to evolve resistance against — the same reason this whole class of "antimicrobial peptides" is studied as an antibiotic alternative. The activity is broad: gram-positive and gram-negative bacteria, some fungi, and enveloped viruses.^[1] Evidence level: established biochemistry and in vitro.

2. Anti-biofilm activity (in vitro)

Biofilms are the slimy, armored communities bacteria build on wounds, medical devices, and mucosal surfaces; they can be 100-1,000 times more resistant to antibiotics than free-floating bacteria. In a landmark lab study, LL-37 prevented Pseudomonas aeruginosa biofilm formation at just 0.5 µg/mL — far below the concentration needed to actually kill the bacteria (its MIC of 64 µg/mL). It worked by reducing bacterial attachment, boosting "twitching" motility so cells did not settle, and switching off quorum-sensing genes bacteria use to coordinate biofilms.^[3] This is one of the most cited reasons for research interest in LL-37. Evidence level: in vitro only — no human biofilm trials.

3. Immune signaling and wound healing

Beyond killing, LL-37 acts as a chemoattractant that pulls neutrophils, monocytes, and T cells toward a threat, neutralizes bacterial endotoxin (LPS) to dampen the inflammatory overreaction to gram-negative bacteria, and promotes angiogenesis (new blood-vessel growth), keratinocyte migration, and re-epithelialization — all core steps of closing a wound.^[1] This multifunctional profile is why one review called LL-37 a "factotum" — a jack-of-all-trades peptide.^[1] Evidence level: in vitro and animal, with topical human wound data described below.

4. The concentration switch — the mechanism that matters most for safety

Here is the piece most vendor pages skip. LL-37's behavior reverses with concentration. At low, near-physiological levels it is immunomodulatory and protective; at substantially higher concentrations it becomes pro-inflammatory.^[4] This is not a minor footnote — it is the defining feature of the molecule. It shows up directly in the human dosing data (the highest tested dose in the leg-ulcer trial worked worse than placebo, discussed below) and it underlies why LL-37 is implicated in driving autoimmune inflammation when it accumulates. Unlike most peptides, where a modest overdose just wastes material, an LL-37 overdose can flip the mechanism from helping to harming.

What we do NOT know

There is no established human pharmacokinetics for injected LL-37 (how a dose is absorbed, distributed, and cleared in people), no confirmed effective systemic dose, and no long-term human safety data for any route other than topical. The mechanisms above are real, published, and mostly reproducible — but the leap from "the body uses this molecule" to "injecting a synthetic copy is safe and helpful" has not been made by controlled human research.

How to read this section: for each area we give the plain-English claim, the mechanism, the population actually studied, the observed effect, and the limitation. The single most important thing to understand is that LL-37's only controlled human evidence is topical wound healing — and even that is mixed. Everything else (antimicrobial, biofilm, immune) is lab and tissue data, not human treatment outcomes.

Wound healing — the only area with human trials (topical)

Claim: topical LL-37 may speed the closing of stubborn, non-healing venous leg ulcers. Mechanism: local antimicrobial action plus angiogenesis and keratinocyte migration. Population and effect: In a first-in-man randomized, placebo-controlled trial of 34 patients with hard-to-heal venous leg ulcers, LL-37 was applied topically twice weekly for four weeks at 0.5, 1.6, or 3.2 mg/mL. The lowest dose (0.5 mg/mL) produced roughly a six-fold higher healing-rate constant versus placebo (p=0.003) and a 68% mean reduction in ulcer area. The middle dose (1.6 mg/mL) gave about a three-fold effect (p=0.088, 50% reduction). Strikingly, the highest dose (3.2 mg/mL) was no better than placebo — a clear inverted, biphasic dose-response. No local or systemic safety concerns were reported.^[5] Limitation: small, topical, single wound type — and the inverted curve is a warning, not a bonus.

The larger follow-up tells a more sobering story. In the phase IIb HEAL trial of 148 venous-leg-ulcer patients, topical LL-37 at 0.5 or 1.6 mg/mL did not beat placebo on the primary healing endpoint in the full population. A benefit appeared only in a post-hoc subgroup with large wounds (≥10 cm²) — a hypothesis-generating signal, not a confirmed result. The drug was well tolerated and safe at both doses over 13 weeks of treatment plus four months of follow-up.^[6] Bottom line: the best human evidence LL-37 has is a promising early trial that a larger, better-powered trial failed to fully confirm — and all of it is topical, not injected.

Broad-spectrum antimicrobial activity

Claim: kills a wide range of bacteria, fungi, and enveloped viruses. Mechanism: membrane pore formation. Population: in vitro and biochemical studies. Effect: documented activity against gram-positive and gram-negative bacteria, Candida, and enveloped viruses, with resistance being difficult to develop because the target is the membrane itself.^[1][2] Limitation: laboratory data. There is no human trial of LL-37 for treating a systemic or localized infection, and the injectable protocols people use for this are entirely unvalidated.

Biofilm disruption

Claim: can prevent and break down bacterial biofilms that shrug off antibiotics. Mechanism: reduced attachment, increased motility, suppressed quorum sensing. Population: P. aeruginosa in vitro. Effect: biofilm formation prevented at 0.5 µg/mL, far below the killing concentration, with effects on pre-grown biofilms too.^[3] Limitation: a single in vitro model; no human data on biofilm-related disease.

Immune modulation

Claim: tunes the immune response — recruiting immune cells, neutralizing endotoxin, bridging innate and adaptive immunity. Mechanism: chemotaxis and cytokine modulation. Population: cell and tissue studies. Effect: real and well-characterized as a signaling molecule.^[1] Limitation: "modulates the immune system" cuts both ways — the same signaling that could help clear an infection is the signaling implicated in autoimmune disease (see Side Effects). For other immune-modulating peptides with different profiles, see KPV and thymosin beta-4.

The honest bottom line on "benefits"

• Human efficacy evidence exists only for topical wound healing, and the larger trial did not confirm the smaller one's benefit.^[6]
• Antimicrobial, biofilm, and immune claims are in vitro / tissue-level — biologically real, but not human treatment outcomes.
• The injectable protocols sold and discussed online have zero human trial support. Every human dose-finding datapoint we have is topical.
• More is not better. The one human dose-response we have is inverted: the highest dose failed.^[5]

Read this first: there is no clinically validated dose for injected LL-37, because no human trial has ever tested an injectable version. The only human dose-finding data in existence are topical: twice-weekly application at 0.5, 1.6, or 3.2 mg/mL directly onto leg ulcers, where the lowest concentration worked best and the highest failed.^[5] The subcutaneous protocols below reflect what circulates in the research-peptide community; they are extrapolations, not trial-derived, and we describe them for harm reduction and completeness, not as medical guidance.

What the human data actually support (topical)

Concentration	Application	Human result
0.5 mg/mL	Twice weekly, topical, 4 weeks	Best result — ~6x healing rate vs placebo, 68% area reduction[5]
1.6 mg/mL	Twice weekly, topical, 4 weeks	Intermediate (p=0.088); no full-population benefit in the larger trial[6]
3.2 mg/mL	Twice weekly, topical, 4 weeks	No better than placebo — the inverted dose-response[5]

The single clearest lesson from human data: with LL-37, the lowest effective concentration is the goal, and pushing the dose up can erase the benefit entirely.

Community subcutaneous protocols (extrapolated, NOT validated)

Protocol	Commonly cited dose	Frequency	Duration
Antimicrobial / immune	50-100 mcg	Once daily	2-4 weeks
Wound / recovery	50-100 mcg	Once daily	2-4 weeks

Community doses are kept deliberately low — far lower than for most peptides — precisely because of the pro-inflammatory switch at higher concentrations. Cycles are kept short (2-4 weeks) because sustained elevation of an immune-activating cathelicidin is exactly the scenario mechanistically linked to autoimmune inflammation. None of this is a recommendation to self-inject an unapproved compound; it is a description of how those protocols are structured.

Reconstitution math, with a worked example

LL-37 ships as a lyophilized (freeze-dried) powder, commonly in 5 mg vials, that must be mixed with bacteriostatic water before use. The core formula:

Concentration (mcg/mL) = vial amount (mcg) ÷ water added (mL)

Worked example: take a 5 mg vial (5,000 mcg) and add 2.5 mL of bacteriostatic water. That gives 5,000 ÷ 2.5 = 2,000 mcg/mL. To draw a 100 mcg dose: 100 ÷ 2,000 = 0.05 mL, which is 5 units on a standard 100-unit insulin syringe.

Vial	BAC water	Concentration	100 mcg dose
5 mg	2.5 mL	2,000 mcg/mL	0.05 mL (5 units)
5 mg	5 mL	1,000 mcg/mL	0.10 mL (10 units)

Use the peptide calculator and bacteriostatic water calculator to check volumes, and the reconstitution guide for a step-by-step walkthrough. Because LL-37's activity flips with concentration, dose accuracy matters more here than with almost any other peptide — a sloppy reconstitution is not just wasted material, it can change what the molecule does.

Storage

• Lyophilized: store at -20°C. LL-37 can aggregate and lose activity at higher temperatures.
• Reconstituted: refrigerate at 2-8°C and use within about 14 days — a shorter window than many peptides, due to stability concerns.
• Avoid repeated freeze-thaw cycles; aliquot into single-use portions if needed. See the peptide storage guide.

Straight talk: the topical human trials found LL-37 well tolerated and safe at the tested concentrations.^[5][6] But those trials put a low concentration on the skin twice a week — a very different exposure from daily injections. The defining safety issue for LL-37 is its dose-dependent switch: at higher concentrations it stops being immune-balancing and becomes pro-inflammatory,^[4] and elevated LL-37 is mechanistically tied to several autoimmune diseases. This is the rare peptide where the biggest risk is not a contaminant — it is the molecule itself, at the wrong dose, in the wrong person.

Reported side effects

Effect	Frequency	Mechanism
Injection-site reaction (redness, warmth, soreness)	Common	Local immune activation — more pronounced than with other peptides because LL-37 is itself an immune-stimulating molecule
Localized swelling / induration	Common at higher doses	Local inflammatory cascade
Transient fatigue	Reported	Cytokine release; a mild flu-like response
Low-grade fever / chills	Rare	Higher doses; cytokine release
Worsening of pre-existing skin condition	Reported	Particularly psoriasis (see below)
Allergic / hypersensitivity reaction	Rare	Discontinue immediately

The controlled human data on injected LL-37 is essentially nonexistent, so most of the injection-related observations above come from real-world peptide use rather than trials. The topical trials, by contrast, are the reassuring part of the record — safe at the doses tested, on the skin.

Autoimmune associations — why psoriasis and lupus patients should avoid it

This is the most clinically important section on the page. LL-37 is not just theoretically risky in autoimmune disease — it is a documented driver of it:

• Psoriasis: LL-37 is a confirmed T-cell autoantigen in psoriasis. About two-thirds of patients with moderate-to-severe plaque psoriasis carry circulating CD4+ and CD8+ T cells specific for LL-37 that produce IFN-gamma and Th17 cytokines, and these correlate with disease activity.^[7] Adding exogenous LL-37 to that picture is pouring fuel on the fire. Contraindicated.
• Systemic lupus erythematosus (SLE): LL-37-DNA complexes drive the interferon signature of lupus; this is an active area of autoimmune research and a strong reason for caution.
• Rosacea: abnormally processed LL-37 is implicated in the inflammation of rosacea.
• Atherosclerosis: LL-37 (hCAP18) transcript is about six-fold higher in human atherosclerotic lesions than in normal arteries, expressed mainly by macrophages and endothelial cells, where it induces the adhesion molecule ICAM-1 and the chemokine MCP-1 — an active role in plaque inflammation.^[8]

Implication for users: anyone with psoriasis, lupus, rheumatoid arthritis, rosacea, severe atherosclerotic cardiovascular disease, or any active autoimmune inflammatory condition should not use exogenous LL-37. The mechanistic evidence is strong enough that this is more than precaution — exogenous LL-37 could plausibly worsen these conditions.

Why dose accuracy matters more for LL-37

Most peptides have a wide therapeutic window where a little extra changes nothing. LL-37 does not. The switch from immunomodulatory to pro-inflammatory is sharp and concentration-dependent,^[4] and the one human dose-response we have is inverted — the highest tested dose failed.^[5] Practical implications:

• Start at the low end of any protocol and resist the urge to "up the dose if it's not working." At higher doses LL-37 may not just stop helping — it may flip pro-inflammatory.
• Use precise reconstitution math (see the peptide calculator) and buy only from sources with verified peptide content.
• Stop sooner rather than later if you develop prominent systemic inflammatory symptoms — fevers, chills, prolonged fatigue, or new joint/skin symptoms.

Contraindications and drug interactions

• Psoriasis, SLE, RA, rosacea or any active autoimmune inflammatory disease — strong contraindication.
• Severe atherosclerotic cardiovascular disease — relative contraindication given LL-37's role in plaque inflammation.^[8]
• Pregnancy and breastfeeding: no controlled data. Avoid.
• Active malignancy: mixed mechanistic data — LL-37 has both pro- and anti-tumorigenic effects across cancer types. Discuss with oncology.
• Immunosuppressant medications (methotrexate, biologics, cyclosporine): LL-37 opposes the therapeutic intent — avoid combining.
• Other immune-stimulating peptides (e.g. thymosin alpha-1): theoretical additive immune activation; not recommended together.

What to do if you experience side effects

• Significant injection-site inflammation: reduce dose, rotate sites, review technique. If recurrent, discontinue.
• Flu-like symptoms (fever, chills, fatigue): hold doses for 5-7 days; resume at a lower dose only if symptoms fully resolve, and discontinue if they recur.
• New or worsening skin lesions: stop immediately and seek dermatology evaluation — LL-37 is mechanistically linked to psoriasis.^[7]
• New joint pain, rash, or systemic symptoms: stop and evaluate for emerging autoimmunity; consult a clinician if symptoms persist.
• Allergic reaction: discontinue immediately and seek emergency care.

For broader context, see Are Peptides Safe? and Peptide Side Effects.

Why this section matters: LL-37 is an unregulated research compound, so purity and identity vary widely between suppliers. And because LL-37's activity is so concentration-sensitive, a vial that contains less (or more) peptide than the label claims is not just poor value — it can change what the molecule does in your body. Verified content is not optional here.

What a credible product should show

• Third-party COA: independent HPLC purity testing (look for ≥95-98%) plus mass-spectrometry identity confirming the expected molecular weight (~4,493 Da for LL-37).
• Batch-specific results: the Certificate of Analysis should reference the exact lot you are buying, not a generic sample.
• Endotoxin testing (LAL): important for anything intended to be injected — and doubly relevant for an immune-active peptide, since endotoxin contamination would itself provoke inflammation.
• Proper form and packaging: lyophilized powder in a sealed, light-protected vial, shipped cold where possible.

Red flags

• No COA, or a COA from the seller rather than an independent lab
• Pre-mixed "ready to use" liquid (shorter shelf life and higher contamination risk — worse for a stability-sensitive peptide like LL-37)
• Prices far below the market (LL-37 is a large 37-residue peptide and genuinely expensive to synthesize)
• Explicit human-use or medical claims, which signal a non-compliant, higher-risk vendor

Legal and regulatory status (2026)

• Not FDA-approved for any indication. There is no approved injectable or systemic LL-37 product; it has only been tested in humans as a topical wound treatment and never approved.
• Research chemical only: it is sold for laboratory research, not for human use, and is not a licensed drug.
• Not on the July 2026 FDA 503A compounding advisory list (the seven peptides reviewed were BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax). LL-37 simply remains in the unapproved category.
• Not a controlled substance: LL-37 is not DEA-scheduled.

For the complete legal picture, read Are Peptides Legal?

Quick answer: LL-37 is one of the more expensive research peptides because it is large (37 amino acids) and harder to synthesize than small peptides like BPC-157. A 5 mg vial commonly runs $60-130, with wide variation by supplier and purity.

Item	Typical cost
5 mg vial (research grade)	$60-130
Bacteriostatic water	$8-15
Insulin syringes (box)	$10-15

Because LL-37 is so concentration-sensitive, the temptation to buy the cheapest vial is exactly backwards — an untested, mislabeled vial is the most expensive mistake you can make with this particular peptide. Price should never outweigh a verifiable, batch-specific third-party COA.